Fluticasone propionate inhibits lipopolysaccharide-induced proinflammatory response in human cystic fibrosis airway grafts.
Airway inflammation, one of the major factors leading to lung damage in cystic fibrosis (CF) patients, is associated with an abnormal increase in proinflammatory cytokines. In this work, we demonstrate the increased release of the proinflammatory cytokines after lipopolysaccharide (LPS) stimulation: human interleukin (hIL)-8 in CF and non-CF airway xenografts, and hIL-6 and human growth-related oncogene-alpha (hGRO-alpha), which could be only analyzed in non-CF xenografts. Under basal conditions, we observed that hIL-8 was higher in CF xenografts compared with non-CF. We also report the anti-inflammatory effect of a glucocorticoid, fluticasone propionate (FP), on CF airway epithelium using a humanized model of airway inflammation developed in nude mice. In CF and non-CF tracheal xenografts, airway inflammation was induced by inoculating Pseudomonas aeruginosa LPS (4 h; 1 microg/ml) in the lumen of the xenografts. FP pretreatment (2 h; 10(-8) M) followed by P. aeruginosa LPS stimulation induced a significant reduction of LPS-induced hIL-8 release in airway liquid collected from CF and non-CF tracheal xenografts (85 and 80%, respectively). In non-CF tracheal xenografts, FP treatment before LPS stimulation induced a significant decrease in hIL-6 and hGRO-alpha. From these data, we suggest that FP exerts anti-inflammatory properties that may be appropriate to CF therapy, at an early stage of the disease. In addition, these results demonstrate that the humanized airway model of inflammation provides a relevant tool for analyzing the effects of anti-inflammatory drugs in different diseases in which airway inflammation is implicated.
Escotte
Sandie
S
Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 514, IFR 53, CHU Maison Blanche, Université de Reims, 45 rue Cognacq-Jay, 51092 Reims Cedex, France.
Danel
Claire
C
Gaillard
Dominique
D
Benoit
Sylvie
S
Jacquot
Jacky
J
Dusser
Daniel
D
Triglia
Jean-Michel
JM
Majer-Teboul
Caroline
C
Puchelle
Edith
E
D000730:Androstadienes / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001826:Body Fluids / Q000502:physiology; D002648:Child; D003550:Cystic Fibrosis / Q000473:pathology*; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007124:Immunoenzyme Techniques; D007249:Inflammation / Q000473:pathology*; D016209:Interleukin-8 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D008168:Lung / Q000473:pathology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011550:Pseudomonas aeruginosa / Q000502:physiology; D014132:Trachea / Q000502:physiology / Q000637:transplantation; D014183:Transplantation, Heterologous
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D016209:Interleukin-8; D008070:Lipopolysaccharides; D000068298:Fluticasone